证券代码：300813 证券简称：泰林生物 公告编号：2025-057 浙江泰林生物技术股份有限公司 关于持股 5%以上股东暨控股股东、实际控制人的一致行动人 减持股份预披露公告 公司持股 5%以上股东暨控股股东、实际控制人的一致行动人青岛高得投资 合伙企业（有限合伙）保证向本公司提供的信息内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 持有本公司7,278,070股（占公司总股本6.01%）的持股5%以上股东暨控股股 东、实际控制人的一致行动人青岛高得投资合伙企业（有限合伙）（曾用名：宁 波高得股权投资管理合伙企业（有限合伙），以下简称"高得投资"）计划通过 集中竞价、大宗交易或两者相结合等方式于本减持计划公告之日起15个交易日后 的3个月内减持公司股份不超过1,819,517股，占公司总股本的1.50%，其中，通 过证券交易所集中竞价交易方式进行减持的，任意连续90个自然日内减持股份的 总数不超过公司股份总数的1%；通过大宗交易方式进行减持的，任意连续90个自 然日内减持股份的总数不 ...

泰林生物（300813）公告，公司控股股东、实际控制人叶大林先生以协议转让的方式转让给倪卫菊女士 的1210万股(占公司总股本的9.9836%)已于2025年7月15日办理完成过户登记。倪卫菊女士承诺在过户完 成之日起12个月内不会以任何方式主动减持本次转让中取得的股份。此次转让不涉及二级市场减持，不 会导致公司控股股东及实际控制人发生变化。 ...

证券代码：300813 证券简称：泰林生物 公告编号：2025-056 浙江泰林生物技术股份有限公司 关于控股股东、实际控制人之间内部协议转让股份完成过户 登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 东、实际控制人叶大林先生、倪卫菊女士提供的中国证券登记结算有限责任公司 出具的《证券过户登记确认书》，倪卫菊女士以协议转让的方式受让叶大林先生 所持有的公司 12,100,000 股（占公司总股本的 9.9836%），已于 2025 年 7 月 15 日办理完成过户登记（以下简称"本次协议转让"）。 次转让中取得的股份。 女士之间的内部转让，不涉及二级市场减持，不会导致叶大林先生、倪卫菊女士 及其一致行动人合计持股数量和比例发生变化。 发生变化，不会对公司财务状况、持续经营情况产生影响，同时也不存在损害公 司及中小投资者利益的情形。 一、协议转让概述 公司控股股东、实际控制人叶大林先生与公司控股股东、实际控制人倪卫菊 女士于 2025 年 5 月 30 日签订了《股份转让协议》。公司控股股东、实际控制人 叶大林先生拟将其持有公司的 12 ...

证券代码：300813 证券简称：泰林生物 公告编号：2025-056 关于控股股东、实际控制人之间内部协议转让股份完成过户 登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 浙江泰林生物技术股份有限公司 1．浙江泰林生物技术股份有限公司（以下简称"公司"）收到公司控股股 东、实际控制人叶大林先生、倪卫菊女士提供的中国证券登记结算有限责任公司 出具的《证券过户登记确认书》，倪卫菊女士以协议转让的方式受让叶大林先生 所持有的公司 12,100,000 股（占公司总股本的 9.9836%），已于 2025 年 7 月 15 日办理完成过户登记（以下简称"本次协议转让"）。 2．倪卫菊女士承诺在过户完成之日起 12 个月内不会以任何方式主动减持本 次转让中取得的股份。 3．本次协议转让事项属于公司控股股东、实际控制人叶大林先生、倪卫菊 女士之间的内部转让，不涉及二级市场减持，不会导致叶大林先生、倪卫菊女士 及其一致行动人合计持股数量和比例发生变化。 4．本次股份转让不触及要约收购，亦不会导致公司控股股东及实际控制人 发生变化，不会对公司财务状况 ...

证券代码：300813 证券简称：泰林生物 公告编号：2025-055 浙江泰林生物技术股份有限公司 关于全资子公司变更注册资本并完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江泰林生物技术股份有限公司（以下简称"公司"）于2025年6月13日召 开第四届董事会第八次会议，审议通过了《关于使用募集资金向全资子公司增资 的议案》。本次增资完成后，浙江泰林新材料有限公司（以下简称"泰林新材料"） 的注册资本由1,000万元变更为10,000万元，仍为公司全资子公司。具体内容详 见披露于巨潮资讯网的《关于使用募集资金向全资子公司增资的公告》（公告编 号：2025-045）。 近日泰林新材料已完成工商变更登记手续并取得了杭州市富阳区市场监督 管理局核发的《营业执照》，相关变更情况如下： 除上述注册资本变更外，其他工商登记信息不变。 二、本次变更后的《营业执照》相关登记信息 1．公司名称：浙江泰林新材料有限公司 5．法定代表人：沈志林 6．注册资本：壹亿元整 7．住所：浙江省杭州市富阳区春江街道富春湾大道 2723 号 17 幢 578 号 ...

Group 1 - The core viewpoint of the news highlights that Tailin Bio's stock closed at 21.03 yuan, down 1.73%, with a rolling PE ratio of 238.08 times, and a total market value of 2.549 billion yuan [1] - In terms of industry comparison, the average PE ratio for the medical device industry is 51.05 times, with a median of 36.62 times, placing Tailin Bio at the 117th position [1][3] - The net outflow of main funds for Tailin Bio on July 4 was 2.3092 million yuan, with a total outflow of 23.9872 million yuan over the past five days [1] Group 2 - Tailin Bio specializes in the research, production, and promotion of products related to microbiological testing and pollution control, innovative drug development, and process analysis, serving various industries including biomedicine, healthcare, food and beverage, and environmental protection [2] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 66.939 million yuan, a year-on-year decrease of 16.33%, and a net profit of 3.5282 million yuan, down 39.93%, with a sales gross margin of 49.27% [2]

证券代码：300813 证券简称：泰林生物 公告编号：2025-054 浙江泰林生物技术股份有限公司 关于取得专利证书及计算机软件著作权登记证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江泰林生物技术股份有限公司（以下简称"公司"）全资子公司浙江泰林 生命科学有限公司（以下简称"泰林生命科学"）、浙江泰林医学工程有限公司（以 下简称"泰林医学工程"）、浙江泰林分析仪器有限公司（以下简称"泰林分析仪 器"）、浙江泰林医疗器械有限公司（以下简称"泰林医疗器械"）于近期共取得 了 17 项专利证书（其中发明专利 2 项）以及 1 项计算机软件著作权登记证书， 具体情况如下： | 序号 | 软件名称 | 著作权人 | 证书号 | 首次发表日 | 登记日期 | 权利 取得 | 权利 | 登记号 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 期 | | 方式 | 范围 | | | 1 | 藻类/两 虫智能分 | 泰林生命 | 软著登字第 15744971 | 2024 ...

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

证券代码：300813 证券简称：泰林生物 公告编号：2025-053 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、对外投资概述 浙江泰林生物技术股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开第四届董事会第七次会议、第四届监事会第七次会议，于 2025 年 5 月 19 日召开 2024 年年度股东大会，审议通过了《关于 2021 年向不特定对象发行可转 换公司债券募集资金投资项目结项并将节余募集资金投入新项目及永久补充流 动资金的议案》《关于拟与杭州富春湾新城管理委员会签订高性能过滤器及配套 功 能 膜 产 业 化 项 目 合 同 书 的 议 案 》， 具 体 内 容 详 见 公 司 在 巨 潮 资 讯 网 （http://www.cninfo.com.cn）披露的《关于 2021 年向不特定对象发行可转换 公司债券募集资金投资项目结项并将节余募集资金投入新项目及永久补充流动 资金的公告》（公告编号：2025-030）、《关于拟与杭州富春湾新城管理委员会签 订高性能过滤器及配套功能膜产业化项目合同书暨对外投资的公告》（公告编号 ...

Core Viewpoint - The legal opinion letter from Grandall Law Firm confirms that the procedures and results of Zhejiang Tailin Biotechnology Co., Ltd.'s 2025 Second Extraordinary General Meeting of Shareholders are in compliance with relevant laws and regulations [4][11]. Group 1: Meeting Procedures - The meeting was convened following the approval of the proposal to hold the 2025 Second Extraordinary General Meeting by the eighth meeting of the fourth board of directors [5]. - The meeting notice included details such as the time, location, convenor, voting methods, and agenda, ensuring shareholders could attend in person or via proxy [5][6]. - The actual time and location of the meeting matched the notice, and the procedures adhered to the requirements of the Company Law and other relevant regulations [6]. Group 2: Attendance and Voting - A total of 79 participants attended the meeting, representing 68,047,805 shares, which is 56.1454% of the total voting shares [8]. - Among the attendees, 74 were small investors, holding 572,207 shares, accounting for 0.4721% of the total voting shares [8]. - The voting process combined on-site and online methods, with specific time slots for online voting clearly outlined in the meeting notice [6][10]. Group 3: Resolutions and Voting Results - The meeting reviewed and voted on the agenda items as stated in the notice, with the results aligning with the announced agenda [9]. - The voting results showed that 67,957,442 shares were in favor of the resolutions, representing a significant majority of the votes cast [10]. - The resolutions passed were ordinary resolutions, requiring a simple majority for approval, and the results were announced immediately after the voting concluded [10][11].